Protagonic Therapeutics, Inc. Warrant (PTIXW)
OTC PINK OTC PINK Primary Summary
PTIXW Chart
Protagonic Therapeutics, Inc. Warrant Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 100,000 | $2,560 | $3,000 | $440 | 17.19% |
Protagonic Therapeutics, Inc. Warrant (PTIXW) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Protagonic Therapeutics, Inc. Warrant Profile
| Biotechnology Industry | Healthcare Sector | Garo H. Armen CEO | OTC PINK Exchange | 74365N111 CUSIP |
| US Country | 1 Employees | - Last Dividend | - Last Split | 27 Apr 2021 IPO Date |
Overview
Protagenic Therapeutics, Inc. is a biopharmaceutical company deeply engaged in the pioneering field of creating innovative therapeutics aimed at treating a range of stress-related neuropsychiatric and mood disorders. With its roots firmly planted in the bustling heart of New York, New York, the company is at the forefront of biotechnological advancement, leveraging cutting-edge science to understand and mitigate the complex mechanisms that underlie various mental health conditions. The focus on stress-related disorders positions Protagenic Therapeutics, Inc. as a beacon of hope for countless individuals seeking relief from the often debilitating symptoms that characterize these conditions.
Products and Services
At the core of Protagenic Therapeutics, Inc.’s product pipeline is their lead compound, PT00114. This innovative therapeutic is a synthesized variant of an endogenous brain signaling peptide, known as teneurin carboxy-terminal associated peptide. The peptide plays a crucial role in the brain's natural stress response mechanisms, and the synthetic form developed by Protagenic Therapeutics aims to emulate and enhance its beneficial effects.
- PT00114: A cutting-edge therapeutic designed to address stress-related neuropsychiatric and mood disorders. PT00114 works by mimicking the effects of teneurin carboxy-terminal associated peptide, a natural compound in the brain that helps regulate stress responses. By dampening overactive stress responses, this synthetic peptide offers a promising avenue for treatment, potentially offering relief to millions struggling with these challenging conditions. The development and implementation of PT00114 underline Protagenic Therapeutics, Inc.’s commitment to advancing mental health care through innovative biotechnological solutions.
